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Long-term memory cellular immune response 
to dengue virus after a natural primary infection 
Beatriz Sierra,(‘) Gissel Garcia,(l) Ana B. Perez,(‘) Luis Morier,(l) Rayner Rodriguez,(l) 
Mayling Alvarez,(‘) and Maria G. GuzmBn(i) 
Objectives: This study was conducted to examine the memory T-cell response to dengue virus 20 years after a primary 
infection. We took advantage of the exceptional epidemiologic situation in Cuba, where the population initially 
suffered two large successive epidemics due to dengue virus 1 and 2 respectively over a 4-year period. Thereafter, 
no dengue virus circulation was subsequently observed, except for the Santiago de Cuba municipality. 
Design: T-cell response was evaluated in peripheral blood mononuclear cells (PBMCs) from 20 individuals with 
history of a primary infection by dengue virus 1 or 2. Methods previously shown to induce lymphoproliferation of 
CD4’ memory T-cell subpopulations were used. We evaluated the proliferative responses generated in those PBMCs 
after stimulation with dengue virus 1,2,3 and 4 antigens in a serotype-specific and serotype-crossreactive way. 
Results: Serotype-specific and serotype-crossreactive lymphoproliferative responses in all PBMCs donated by dengue 
immune donors were observed. The serotype-crossreactive response for dengue 2 was stronger than for the rest of 
the serotypes. 
Conclusions: This is the first report of cellular memory lymphocyte response specific for dengue virus detected 20 
years after a primary infection by dengue. 
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INTRODUCTION 
Although the circulation of dengue virus has been widely 
documented in the region of the Americas, reports of 
clinical syndromes caused by dengue virus infection 
in Cuba have been sporadic.’ However, in 1977 Cuba 
suffered an extensive epidemic of dengue fever (DF), 
caused by dengue virus type 1.2 This epidemic was 
followed by a dengue hemorrhagic feveridengue shock 
syndrome (DHF/DSS) outbreak in 1981, caused by 
dengue 2 virus, which produced a high number of cases 
and fatalities.3 
The circulation of dengue had not been subsequently 
observed until January 1997, when a focal dengue 
epidemic in Cuba produced 205 classical DHF/DSS cases, 
with 12 deaths in persons 18 years and older in Santiago 
de Cuba, the vast majority of them with a secondary-type 
antibody response. 3,4 The epidemic was almost controlled 
by August 1997. Effective vector control measures 
arrested the spread of the disease to other parts of the 
country.” For these reasons, the Cuban experience may be 
considered unique: two large successive epidemics due to 
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dengue virus types 1 and 2 respectively occurred 4 years 
apart, followed by several years in which no dengue virus 
circulation was detected. 
These exceptional circumstances offered us the 
possibility to explore the memory T-cell immune response 
to dengue virus 20 years after the primary infection. 
MATERIALS AND METHODS 
We studied 20 Cuban individuals from Havana City, 
with previous infection by dengue 1 and dengue 2 during 
the epidemics which occurred in Cuba in 1977 and 1981, 
respectively, with titers of l/40 or higher of antibodies to 
dengue virus by ELISA.6 Ten of them were primary 
cases of dengue 1 and 10 of dengue 2, as shown using 
plaque reduction neutralization: sera were tested by 
neutralization test at dilutions between l/10 and l/1000 
for their ability to neutralize dengue virus by semimicro 
methods in BHK21 cells.’ 
PBMCs from five individuals without antibodies to 
dengue virus were used as negative controls. 
Dengue 1 (Hawaii strain), dengue 2 (New Guinea- 
C strain), dengue 3 (H87 strain) and dengue 4 (H242 
strain) were used to produce antigens for the lympho- 
proliferation assay (LPA). These antigens were purified 
from infected suckling-mouse brains by equilibrium 
centrifugation in a 1560% (w/u) sucrose gradient in 
TNE.s The negative control antigen was prepared 
similarly but from uninfected suckling-mouse brains. 
Purified antigens were inactivated, sterilized, aliquoted, 
and frozen at -70°C. 
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All PBMCs were purified by density gradient centri- 
fugation.9 To measure the proliferative response, cells 
(1 x lo5 in 100 uL of supplemented RPM1 1640) were 
cultured for 5 days at 37°C in the presence of dengue 
virus 1,2,3 and 4 or control uninfected suckling-mouse 
brain (20 ug/mL) and phytohemagglutinin (5 ug/mL) 
in supplemented RPM1 1640 medium and pulsed with 
1 uCi of tritiated thymidine ([3H]TdR, Amersham, UK) 
for 6 h before harvest. [3H]TdR incorporation was mea- 
sured in a liquid scintillation counter and stimulation 
index was calculated.lO 
Anti-CD8 and Anti-CD4 antibodies directly con- 
jugated to fluorescein isothiocyanate (Becton Dickinson 
Co., Mountain View, CA, USA) were used to count 
CD8+ and CD4+ PBMCs in a fluorescence-activated cell 
sorter (FACS 440; Becton Dickinson Co.).” 
RESULTS 
PBMCs obtained from each donor with dengue primary 
infection showed adequate proliferative responses to 
PHA and to dengue virus antigens (Figures 1 and 2). 
Serotype-specific stimulation in all cases and crossre- 
activity in most of them were detected. Control antigen 
did not induce proliferative responses. PBMCs from 
negative controls showed no proliferation in response to 
any of the dengue virus antigens. 
PBMC phenotypes after dengue virus antigen stimu- 
lation determined by FACS showed that 57.54% of the 
cells were CD3+CD4+ T-cells, and 21.79% were CD3+ 
CD8’ (mean values). 
DISCUSSION 
The generation of a cellular immune response after a 
primary dengue virus infection was reported by Kurane 
et al in 1989.‘* Serotype-specific and serotype-cross- 
reactive memory T-lymphocytes have been detected in 
patients after recovering from natural dengue virus 
infection or following immunization with live-atten- 
uated virus vaccines.13 These previous studies were 
performed in areas with high dengue prevalence, where 
frequent reinfections are likely to occur. However, in the 
reviewed literature, no studies exploring the long-term 
memory cellular immune response to dengue virus after 
a natural primary infection have been found. 
The population in Cuba suffered two large epidemics 
due to dengue 1 (1977) and dengue 2 (1981) and no 
other outbreaks were recorded after this time, with the 
exception of a small outbreak in the Santiago de Cuba 
municipality.4 Immediately after this second epidemic, a 
passive dengue surveillance system was established.The 
data recorded from 1982 to 1996 demonstrate that no 
dengue viruses had circulated in the country for those 
14 years, since no anti-flavivirus IgG antibodies were 
detected in sera from children born after 1982.i4 
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Figure 1. Average of stimulation index of the individuals immune to dengue 1 (Dl) and dengue 2 (D2) and controls in response to 
pt$tohemagglutinin (PHA). 
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Figure 2. Average of stimulation index of the individuals immune to dengue 1 (Dl) and dengue 2 (D2) and controls in response to 
the four serotypes of dengue virus. 
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The above-mentioned situation offered us the possi- 
bility to explore the long-term memory T-cell response 
to dengue virus after a natural primary infection. 
Our results confirm the existence of a memory T-cell 
response that exhibits serotype-crossreactive proliferative 
response to dengue virus 20 years after the primary 
dengue infection. To our knowledge, this is the first time 
that a longstanding T-cell response to dengue virus has 
been reported. 
Kurane et alI1 have previously analyzed the dengue 
virus-specific human T-lymphocyte clones for dengue 
serotype-crossreactive specificities.They found a stronger 
crossreactive response to dengue 3 in dengue l-immune 
individuals. In our study, however, we noted the strongest 
serotype-crossreactive response to dengue 2 in dengue 
l-immune donors. 
The analysis of the dengue complex interactions by 
comparison of the protein amino acid sequences showed 
that dengue 1, dengue 3 and dengue 4 are antigenically 
more closely related to each other than to dengue 2.i5 
However, taking into account the important role of 
sequential infection as a risk factor for the development 
of the DHF, secondary heterotypic infection by dengue 
2 has frequently been associated with DHF in dengue l- 
immune patients.16 In the Cuban experience, in both 
DHF epidemics, 1981 and 1997, the sequence of infection 
was the same: dengue 1 followed by dengue 2.3,4 It seems 
that this observation reflects an immunogenic relation- 
ship between dengue 1 and dengue 2 serotypes. 
On the other hand, it is a recognized fact that the 
severity was greater in both the 1981 and 1997 Cuban 
epidemics when compared with those that occurred 
in the American region, caused by the same dengue 
virus serotypes and strain. l’,i* Our results regarding the 
cellular immune response could be related to that event, 
Probably, the same viral and host factors do not operate 
in the same manner among genetically different popu- 
lations. 
Kurane and EnnisI and Rothman and Ennis20 have 
hypothesized that the dengue virus-specific, serotype- 
crossreactive T-lymphocytes, which are activated during 
secondary dengue virus infection, play an important role 
in the pathogenesis of DHF. They are stimulated to 
produce cytokines like IFN-?I, which has a pivotal role 
in this model for DHF immunopathogenesis, and also 
permit, by lysing dengue virus-infected monocytes, 
the release of high levels of cytokines and chemical 
mediators that induce malfunction of vascular endo- 
thelial cells, which in turn produces plasma leakage and 
shock.2’ 
Owing to the intensive dengue infection surveil- 
lance carried out from 1981 to 1997, it became clear that 
DHF/DSS cases in the dengue 2 epidemic in Santiago de 
Cuba in 1997 occurred in persons infected initially with 
dengue 1 in 1977-79. 3,4 This epidemic showed that a 
primary infection is a risk for the development of the 
severest clinical presentation, even 20 years after the 
primary infection. 
Taking into account the above-mentioned model of 
immunopathogenesis, our results may be the first con- 
firmation of the existence of memory crossreactive T- 
lymphocytes 20 years after infection. This could be 
partially responsible for the 205 classical DHF/DSS cases 
with 12 deaths in persons 18 years and older observed 
in Santiago de Cuba, 20 years after the primary in- 
fection. More interestingly, it has been statistically 
demonstrated that a secondary dengue 2 infection occur- 
ring at an interval of 20 years after a dengue 1 primary 
infection can be more severe than a secondary dengue 
2 infection occurring 4 years after a dengue 1 primary 
infection.” The case fatality rate was nearly five-fold 
higher in 1997 than in 1981. A hypothesis is that host- 
related factors, such as time-related changes in immune 
response, may be responsible for the severity differences 
observed.22 The heterotypic long-duration memory T- 
cell response, confirmed in this work, could be involved 
in this time-enhanced severity. 
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